Vandana Singh

Kura Oncology’s Head & Neck Cancer Candidate Shows Promising Results in Pretreated Patients

Kura Oncology Inc (NASDAQ: KURA) has released the latest results from its registration-directed AIM-HN study, showcasing the potential of tipifarnib as a treatment for HRAS mutant head and neck squamous cell carcinoma (HNSCC) in...

Breaking News: FDA Approves Ardelyx’s Revolutionary Kidney Disease Drug

In a major breakthrough, the FDA has granted approval for Ardelyx Inc's groundbreaking drug, Xphozah (tenapanor), as an innovative treatment for chronic kidney disease (CKD) in adults undergoing dialysis. This makes Xphozah the first and only phosphate absorption...

Editas Medicine Faces Challenges in Sickle Cell Therapy Market: Analyst Report

According to a recent analysis by Cantor Fitzgerald, Editas Medicine Inc (EDIT) has been downgraded to Neutral from Overweight. The downgrade comes as Editas' sickle cell therapy, EDIT-301, faces tough competition from Vertex Pharmaceuticals/CRISPR Therapeutics AG's (CRSP) exa-cel...

Cautious Optimism Surrounds Bluebird Bio’s Sickle Cell Therapy: Analyst Highlights Financial Challenges

The Potential of Bluebird Bio's Lovo-Cel in the Sickle Cell Disorder Market Cantor Fitzgerald has recently initiated coverage on Bluebird Bio Inc (NASDAQ: BLUE), shedding light on the promising developments in genetic medicines targeting sickle cell disorder (SCD), particularly...

Why is Monte Rosa Therapeutics Stock Experiencing a Decline Today?

Monte Rosa Therapeutics Inc (GLUE) recently announced a strategic collaboration and licensing agreement with Roche Holdings AG (RHHBY) to develop molecular glue degraders (MGDs) for the treatment of cancer and neurological diseases. While this news may seem positive,...

Why Is Biocept Inc (BIOC) Stock Trading Lower Today?

Biocept Inc (BIOC) has been making headlines today due to its recent filing for Chapter 7 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware. This move comes after the company's consideration of strategic alternatives. The...

Why Mereo BioPharma Stock is Surging Today?

Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO) have recently released interim data from the Phase 2 portion of the Phase 2/3 Orbit study of setrusumab. The data...

Novavax Faces Setback, European Authority Delays Decision On Variant-Tailored COVID-19 Vaccine

Novavax Inc NVAX faces a setback as the European Medicines Agency (EMA) delays a decision on its variant-tailored COVID-19 vaccine. This delay comes at a challenging time for the US-listed biotech, grappling with declining demand for COVID-19 vaccines.The EMA was set to...

Specialty Pharma Firm RVL Pharmaceuticals Subsidiaries File for Bankruptcy

RVL Pharmaceuticals plc's subsidiaries are taking the necessary steps to file for bankruptcy, as part of a prepackaged deal involving lender Athyrium Capital and other key stakeholders. This reorganization plan aims to allow the RVL subsidiaries to reduce their...

Analyst Cautiously Optimistic On Alignment Healthcare, Assesses Journey to Profitability Of Medicare Advantage Firm

Stephens initiated coverage on Alignment Healthcare Inc ALHC, saying it offers growth-oriented small-cap investors pure-play exposure to Medicare Advantage (MA), a catalyst for sustained growth in Managed Care. The analysts Scott Fidel and Raj Kumar have initiated with an Equal Weight rating and a price target of...